{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:48:55Z","timestamp":1787759335496,"version":"build-2784847793"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,9]],"date-time":"2015-09-09T00:00:00Z","timestamp":1441756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hospital Medicine"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p><jats:italic>Acinetobacter baumannii<\/jats:italic> (AB) has evolved a variety of resistance mechanisms and exhibits unpredictable susceptibility patterns, making it difficult to select empiric therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>To examine US secular trends in the resistance of AB in respiratory infections and blood stream infections (BSI) to antimicrobial agents whose effectiveness is supported in the literature<\/jats:p><\/jats:sec><jats:sec><jats:title>DESIGN<\/jats:title><jats:p>Survey.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>We analyzed 3 time periods (2003\u20132005, 2006\u20132008, 2009\u20132012) in Eurofins' The Surveillance Network for resistance of AB to the following antimicrobials: carbapenems (imipenem, meropenem, doripenem), aminoglycosides (tobramycin, amikacin), tetracyclines (minocycline, doxycycline), polymyxins (colistin, polymyxin B), ampicillin\u2010sulbactam, and trimethoprim\u2010sulfamethoxazole. Resistance to \u22653 drug classes defined multidrug resistance (MDR).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>We identified 39,320 AB specimens (81.1% respiratory, 18.9% BSI). The highest prevalence of resistance was to doripenem (90.3%) followed by trimethoprim\u2010sulfamethoxazole (55.3%), and the lowest to colistin (5.3%). Resistance to carbapenems (21.0% in 2003\u20132005 and 47.9% in 2009\u20132012) and colistin (2.8% in 2006\u20132008 to 6.9% in 2009\u20132012) more than doubled. Prevalence of MDR AB rose from 21.4% in 2003 to 2005 to 33.7% in 2006 to 2008, and remained stable at 35.2% in 2009 to 2012. In contrast, resistance to minocycline diminished from 56.5% (2003\u20132005) to 30.5% (2009\u20132012). MDR organisms were most frequent in nursing homes (46.5%), followed by general ward (29.2%), intensive care unit (28.7%), and outpatient setting (26.2%).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Resistance rates among AB to such last\u2010resort antimicrobials as carbapenems and colistin are on the rise, whereas that to minocycline has declined. Nursing homes are a reservoir of resistant AB. These trends should inform not only empiric treatment of serious infections, but also approaches to infection control. <jats:italic>Journal of Hospital Medicine<\/jats:italic> 2016;11:21\u201326. \u00a9 2015 Society of Hospital Medicine.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jhm.2477","type":"journal-article","created":{"date-parts":[[2015,9,9]],"date-time":"2015-09-09T20:19:39Z","timestamp":1441829979000},"page":"21-26","source":"Crossref","is-referenced-by-count":87,"title":["Secular trends in <i>Acinetobacter baumannii<\/i> resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study"],"prefix":"10.1002","volume":"11","author":[{"given":"Marya D.","family":"Zilberberg","sequence":"first","affiliation":[{"name":"EviMed Research Group, LLC Goshen Massachusetts"},{"name":"School of Public Health and Health Sciences University of Massachusetts Amherst Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin H.","family":"Kollef","sequence":"additional","affiliation":[{"name":"Barnes\u2010Jewish Hospital  St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Shorr","sequence":"additional","affiliation":[{"name":"Washington Hospital Center  Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2004.10.001"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4606-4610.2004"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00851-07"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.1.262"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01712153"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0842"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000298158.12101.41"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181fa41a7"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.2.462"},{"key":"e_1_2_6_11_1","unstructured":"Centers for Disease Control and Prevention.Antibiotic resistance threats in the United States 2013. Available at:http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf#page=59. Accessed December 29 2014."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1086\/668770"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-014-0596-8"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01464-06"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-014-0572-6"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/653120"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/650379"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1086\/669523"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1086\/520195"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1512.081341"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-3-3"},{"key":"e_1_2_6_22_1","volume-title":"Performance standards for antimicrobial susceptibility testing: twenty\u2010second informational supplement. CLSI document M100\u2010S22","year":"2012"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_2_6_24_1","unstructured":"CDDEP: The Center for Disease Dynamics Economics and Policy. Resistance map: Acinetobacter baumannii overview. Available at:http:\/\/www.cddep.org\/projects\/resistance_map\/acinetobacter_baumannii_overview. Accessed January 16 2015."},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1086\/667376"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/675612"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.4.1072"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.1.102"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2565(03)71267-3"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2011.09.028"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.3810\/hp.2010.11.347"},{"key":"e_1_2_6_32_1","unstructured":"FriedenT.Centers for Disease Control and Prevention. CDC director blog. The end of antibiotics. Can we come back from the brink? Available at:http:\/\/blogs.cdc.gov\/cdcdirector\/2014\/05\/05\/the-end-of-antibiotics-can-we-come-back-from-the-brink\/. Published May 5 2014. Accessed January 16 2015."}],"container-title":["Journal of Hospital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjhm.2477","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jhm.2477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jhm.2477","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/shmpublications.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jhm.2477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T19:08:36Z","timestamp":1760641716000},"score":1,"resource":{"primary":{"URL":"https:\/\/shmpublications.onlinelibrary.wiley.com\/doi\/10.1002\/jhm.2477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,9]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1002\/jhm.2477"],"URL":"https:\/\/doi.org\/10.1002\/jhm.2477","archive":["Portico"],"relation":{},"ISSN":["1553-5592","1553-5606"],"issn-type":[{"value":"1553-5592","type":"print"},{"value":"1553-5606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,9]]}}}